Skip to main content
. 2019 Jun 4;2019(6):CD013163. doi: 10.1002/14651858.CD013163.pub2

Comparison 3. Alternative lipid emulsion (LE) versus soybean oil‐based lipid emulsion (S‐LE) (see Appendix 3).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
1 Days to regain birth weight 3   Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 MS‐LE vs S‐LE 1 59 Mean Difference (IV, Fixed, 95% CI) 3.0 [‐0.73, 6.73]
1.2 OS‐LE vs S‐LE 3 223 Mean Difference (IV, Fixed, 95% CI) ‐0.19 [‐2.00, 1.62]
2 Growth rate (g/kg/day) 2   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2.1 MS‐LE vs S‐LE 1 60 Mean Difference (IV, Fixed, 95% CI) ‐2.67 [‐8.20, 2.86]
2.2 OS‐LE vs S‐LE 2 123 Mean Difference (IV, Fixed, 95% CI) ‐0.42 [‐5.15, 4.30]
3 Parenteral nutrition‐associated liver disease (PNALD)/cholestasis (conjugated bilirubin ≥ 2 mg/dL) 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
3.1 OS‐LE vs S‐LE 2 159 Risk Ratio (M‐H, Fixed, 95% CI) 1.0 [0.15, 6.82]
3.2 MS‐LE vs S‐LE 1 60 Risk Ratio (M‐H, Fixed, 95% CI) 3.0 [0.13, 70.83]
4 PNALD/cholestasis (conjugated bilirubin ≥ 2 mg/dL): Combined subgroups 2 189 Risk Ratio (M‐H, Fixed, 95% CI) 1.14 [0.22, 5.84]
5 PNALD/cholestasis (any definition) 4   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
5.1 OS‐LE vs S‐LE 4 261 Risk Ratio (M‐H, Fixed, 95% CI) 1.0 [0.26, 3.86]
5.2 MS‐LE vs S‐LE 1 60 Risk Ratio (M‐H, Fixed, 95% CI) 3.0 [0.13, 70.83]
6 PNALD/cholestasis (any definition): Combined subgroups 4 291 Risk Ratio (M‐H, Fixed, 95% CI) 1.08 [0.31, 3.72]
6.1 OS‐LE vs S‐LE 4 291 Risk Ratio (M‐H, Fixed, 95% CI) 1.08 [0.31, 3.72]
7 Death before discharge 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
7.1 OS‐LE vs S‐LE 3 224 Risk Ratio (M‐H, Fixed, 95% CI) 1.0 [0.21, 4.82]
7.2 MS‐LE vs S‐LE 1 60 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Any retinopathy of prematurity 3   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
8.1 OS‐LE vs S‐LE 3 142 Risk Ratio (M‐H, Fixed, 95% CI) 0.98 [0.67, 1.43]
9 Any bronchopulmonary dysplasia 4   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
9.1 OS‐LE vs S‐LE 4 261 Risk Ratio (M‐H, Fixed, 95% CI) 0.69 [0.46, 1.04]
9.2 OS‐LE vs S‐LE (sensitivity analysis) 3 197 Risk Ratio (M‐H, Fixed, 95% CI) 1.01 [0.57, 1.79]
9.3 MS‐LE vs S‐LE 1 60 Risk Ratio (M‐H, Fixed, 95% CI) 1.0 [0.28, 3.63]
10 Chronic lung disease (oxygen requirement at 36 weeks) 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
10.1 OS‐LE vs S‐LE 2 123 Risk Ratio (M‐H, Fixed, 95% CI) 0.59 [0.34, 1.01]
10.2 MS‐LE vs S‐LE 1 60 Risk Ratio (M‐H, Fixed, 95% CI) 1.0 [0.28, 3.63]
11 Duration of ventilation (days) 3   Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 OS‐LE vs S‐LE 3 202 Mean Difference (IV, Fixed, 95% CI) ‐0.20 [‐1.67, 1.26]
12 Duration of supplemental oxygen (days) 2   Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 OS‐LE vs S‐LE 2 102 Mean Difference (IV, Fixed, 95% CI) ‐0.76 [‐16.99, 15.47]
13 Duration of hospital stay (days) 2 164 Mean Difference (IV, Fixed, 95% CI) 0.33 [‐7.44, 8.10]
13.1 OS‐LE vs S‐LE 2 164 Mean Difference (IV, Fixed, 95% CI) 0.33 [‐7.44, 8.10]
14 Need for home oxygen therapy 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
14.1 OS‐LE vs S‐LE 1 64 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
15 Any sepsis (clinical or culture positive (or both)) 5   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
15.1 MS‐LE vs S‐LE 1 60 Risk Ratio (M‐H, Fixed, 95% CI) 2.0 [0.67, 5.94]
15.2 OS‐LE vs S‐LE 5 301 Risk Ratio (M‐H, Fixed, 95% CI) 0.87 [0.56, 1.36]
16 Culture‐positive sepsis 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
16.1 OS‐LE vs S‐LE 2 164 Risk Ratio (M‐H, Fixed, 95% CI) 1.22 [0.54, 2.78]
17 Necrotising enterocolitis (≥ stage 2) 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
17.1 MS‐LE vs S‐LE 1 60 Risk Ratio (M‐H, Fixed, 95% CI) 5.0 [0.25, 99.95]
17.2 OS‐LE vs S‐LE 1 59 Risk Ratio (M‐H, Fixed, 95% CI) 3.1 [0.13, 73.14]
18 Intraventricular haemorrhage (grade III‐IV) 2 104 Risk Ratio (M‐H, Fixed, 95% CI) 0.5 [0.10, 2.61]
18.1 OS‐LE vs S‐LE 2 104 Risk Ratio (M‐H, Fixed, 95% CI) 0.5 [0.10, 2.61]
19 Periventricular leukomalacia 1 64 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.01, 7.89]
19.1 OS‐LE vs S‐LE 1 64 Risk Ratio (M‐H, Fixed, 95% CI) 0.33 [0.01, 7.89]
20 Any patent ductus arteriosus 1   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
20.1 OS‐LE vs S‐LE 1 59 Risk Ratio (M‐H, Fixed, 95% CI) 1.03 [0.63, 1.71]
20.2 MS‐LE vs S‐LE 1 60 Risk Ratio (M‐H, Fixed, 95% CI) 1.13 [0.70, 1.82]
21 Air leaks 1 64 Risk Ratio (M‐H, Fixed, 95% CI) 0.5 [0.05, 5.24]
21.1 OS‐LE vs S‐LE 1 64 Risk Ratio (M‐H, Fixed, 95% CI) 0.5 [0.05, 5.24]
22 Significant jaundice requiring treatment 2   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
22.1 OS‐LE vs S‐LE 2 109 Risk Ratio (M‐H, Fixed, 95% CI) 1.04 [0.52, 2.07]
23 Duration of phototherapy (days) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
23.1 OS‐LE vs S‐LE 1 38 Mean Difference (IV, Fixed, 95% CI) ‐0.10 [‐1.08, 0.88]
24 Hypertriglyceridaemia 4   Risk Ratio (M‐H, Fixed, 95% CI) Subtotals only
24.1 OS‐LE vs S‐LE 3 142 Risk Ratio (M‐H, Fixed, 95% CI) 0.67 [0.12, 3.73]
24.2 MS‐LE vs S‐LE 1 12 Risk Ratio (M‐H, Fixed, 95% CI) 0.0 [0.0, 0.0]
25 Hyperglycaemia 1 64 Risk Ratio (M‐H, Fixed, 95% CI) 1.0 [0.22, 4.59]
25.1 OS‐LE vs S‐LE 1 64 Risk Ratio (M‐H, Fixed, 95% CI) 1.0 [0.22, 4.59]
26 Head growth velocity (cm/week) 1 100 Mean Difference (IV, Fixed, 95% CI) ‐0.08 [‐0.17, 0.01]
26.1 OS‐LE vs S‐LE 1 100 Mean Difference (IV, Fixed, 95% CI) ‐0.08 [‐0.17, 0.01]
27 Conjugated bilirubin levels (µmol/L) 5   Mean Difference (IV, Fixed, 95% CI) Subtotals only
27.1 MS‐LE vs S‐LE 1 60 Mean Difference (IV, Fixed, 95% CI) ‐1.03 [‐4.49, 2.43]
27.2 OS‐LE vs S‐LE 5 310 Mean Difference (IV, Fixed, 95% CI) ‐0.24 [‐1.03, 0.55]